Presentación Conversatorio Covid 1 · Title: Microsoft PowerPoint - Presentación Conversatorio...
41
Mario Chiong Comité Operativo COVID‐19 Conversatorio COVID‐19
Transcript of Presentación Conversatorio Covid 1 · Title: Microsoft PowerPoint - Presentación Conversatorio...
Mario ChiongComité Operativo COVID‐19
Conversatorio COVID‐19
SARS‐CoV2 y Covid‐19
http://covid‐19vis.cmm.uchile.cl/chart
http://covid‐19vis.cmm.uchile.cl/chart
http://covid‐19vis.cmm.uchile.cl/chart
http://covid‐19vis.cmm.uchile.cl/chart
http://covid‐19vis.cmm.uchile.cl/chart
http://covid‐19vis.cmm.uchile.cl/chart
Imagen de la Dra Jeanette Vega, Consejo técnico asesor COVID19
https://covid19entucomuna.cl/regiones/Metropolitana/comunas/Providencia
https://covid19entucomuna.cl/regiones/Metropolitana/comunas/Recoleta
https://covid19entucomuna.cl/regiones/Metropolitana/comunas/Independencia
http://covid‐19vis.cmm.uchile.cl/chart
R0: Qué tan rápido se propaga el virus
1 2 3 4 5DÍANUMERO DE INFECTADOS 1 2 4 8 16
R0 = 2
Formas de contagio de SARS‐Cov‐2
145 m2
53 min73 min
1 m
COVID‐19 Vaccinedeveloper/manufacturer Vaccine
platform
Type of candidate vaccine
Number of doses Timing of
doses
Route ofAdministration
Clinical Stage
Phase 1 Phase 1/2 Phase 2 Phase 3
University ofOxford/AstraZeneca
Non‐ReplicatingViral Vector
ChAdOx1‐S 1 IMPACTR202006922165132 2020‐001072‐15Interim Report
2020‐001228‐32ISRCTN89951424*NCT04516746
CanSino Biological Inc./Beijing Institute of Biotechnology
Non‐Replicating Viral Vector
Adenovirus Type 5 Vector
1 IM ChiCTR2000030906Study Report
ChiCTR2000031781Study Report
NCT04526990NCT04540419
Gamaleya Research Institute
Non‐Replicating Viral Vector
Adeno‐based (rAd26‐S+rAd5‐S)
2 0, 21 days IMNCT04436471NCT04437875Study Report
NCT04530396
Janssen Pharmaceutical Companies
Non‐Replicating Viral Vector
Ad26COVS1 2 0, 56 days IM NCT04436276 NCT04505722(not yet recruiting)
Sinovac Inactivated Inactivated 2 0, 14 days IM NCT04383574NCT04352608
NCT04456595669/UN6.KEP/EC/2020
Wuhan Institute of Biological Products/Sinopharm
Inactivated Inactivated 2 0, 14 or 0, 21 days
IM ChiCTR2000031809Interim Report
ChiCTR2000034780
Beijing Institute of Biological Products/Sinopharm
Inactivated Inactivated 2 0, 14 or 0, 21 days
IM ChiCTR2000032459 ChiCTR2000034780
Moderna/NIAID RNA LNP‐encapsulated mRNA
2 0, 28 days IM NCT04283461Interim Report
NCT04405076 NCT04470427
BioNTech/FosunPharma/Pfizer
RNA 3 LNP‐mRNAs 2 0, 28 days IM 2020‐001038‐36
ChiCTR2000034825NCT04537949 NCT04368728Study Report
Vacunas más promisorias
*Suspendido por reacción adversa en UK por mielitis transversa https://www.who.int/publications/m/item/draft‐landscape‐of‐covid‐19‐candidate‐vaccines
Mario ChiongComité Operativo COVID‐19
Conversatorio COVID‐19
